Andrea Lage

Wuppertal, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Journal: Lancet (London, England)

Published: April 23, 2026

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

Journal: Diabetes, obesity & metabolism

Published: December 23, 2025

Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.

Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.

Journal: European journal of heart failure

Published: November 17, 2025

Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial.

Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial.

Journal: European journal of heart failure

Published: October 21, 2025

Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis.

Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis.

Journal: Journal of the American College of Cardiology

Published: October 19, 2025

Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials.

Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials.

Journal: European heart journal

Published: October 17, 2025

Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.

Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial.

Journal: JAMA cardiology

Published: August 13, 2025

Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.

Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials.

Journal: Journal of the American College of Cardiology

Published: July 14, 2025

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.

Journal: JAMA cardiology

Published: March 30, 2025

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

Journal: European journal of heart failure

Published: December 02, 2024

Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.

Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.

Journal: Kidney international

Published: November 07, 2024

Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.

Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF.

Journal: Journal of the American College of Cardiology

Published: October 10, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026